For research use only
Verdaine

Hormonal Health Research · 8 min read · January 22, 2026

GLP-1 Research: What the Literature Says

A structured read of the GLP-1 and dual-agonist research record.

DE

Dr. Elena Park

Research Director

The receptor and its signaling

GLP-1 receptors are expressed in the pancreas, the brainstem, and the hypothalamus. In preclinical models, receptor activation modulates insulin secretion in a glucose-dependent way, delays gastric emptying, and signals satiety through vagal and central pathways.

The dual-agonist work — adding GIP, amylin, or glucagon signaling to the GLP-1 backbone — is the current frontier. Literature published in the last three years reports additive rather than competing effects across these receptor combinations.

What researchers are studying now

Published studies examine dose-response curves, receptor desensitization timelines, and the behavioral correlates of central GLP-1 signaling. A growing literature investigates long-acting analogs and their pharmacokinetics in different model systems.

Research is not the same as practice, and none of this literature constitutes a health claim. But the depth of the record is now substantial enough that a careful reader can form a grounded understanding of the mechanism.

Editor's note

This article surveys the published literature and does not constitute medical advice or a health claim. Verdaine supplies research peptides for laboratory investigation only.

Keep reading

Join the research community

More from the Journal.

Monthly dispatches — literature summaries, protocol guides, and early access to the Research Academy.